

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 February 2023 (02.02.2023)



(10) International Publication Number
WO 2023/006828 A1

(51) International Patent Classification:

C07K 14/47 (2006.01) A61K 39/00 (2006.01)
A61P 35/00 (2006.01) C07K 14/725 (2006.01)
C07K 16/30 (2006.01)

RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(21) International Application Number:

PCT/EP2022/071104

(22) International Filing Date:

27 July 2022 (27.07.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

21188018.2	27 July 2021 (27.07.2021)	EP
63/203,582	27 July 2021 (27.07.2021)	US
63/335,399	27 April 2022 (27.04.2022)	US

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(71) Applicant: IMMATICS BIOTECHNOLOGIES GMBH
[DE/DE]; Paul-Ehrlich-Str. 15, 72076 Tübingen (DE).

(72) Inventors: **YOUSEF, Sara**; c/o Immatrics Biotechnolo-
gies GmbH, Paul-Ehrlich-Str. 15, 72076 Tübingen (DE). **BRUNK, Fabian**; c/o Immatrics Biotechnologies GmbH,
Paul-Ehrlich-Str. 15, 72076 Tübingen (DE). **MORITZ, Andreas**; c/o Immatrics Biotechnologies GmbH, Paul-
Ehrlich-Str. 15, 72076 Tübingen (DE). **BUNK, Sebastian**;
c/o Immatrics Biotechnologies GmbH, Paul-Ehrlich-Str. 15,
72076 Tübingen (DE). **WAGNER, Claudia**; Paul-Ehrlich-
Str. 15, 72076 Tübingen (DE). **MAURER, Dominik**; Paul-
Ehrlich-Str. 15, 72076 Tübingen (DE). **UNVERDORBEN, Felix**;
c/o Immatrics Biotechnologies GmbH, Paul-Ehrlich-
Str. 15, 72076 Tübingen (DE).

(74) Agent: **ZWICKER, Jörk**; Zwicker Schnappauf & Partner
Patentanwälte PartG mbB, Hansastr. 32, 80686 München
(DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,

(54) Title: ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING CT45

(57) Abstract: The present invention provides an antigen binding protein specifically binding to a CT45 antigenic peptide that is in a complex with a major histocompatibility complex (MHC) protein, wherein the CT45 antigenic peptide comprises or consists of the amino acid sequence of SEQ ID NO: 138 (KIFEMLEGV) and wherein the antigen binding protein comprises a first polypeptide comprising a variable domain VA comprising complementarity determining regions CDRa1, CDRa2 and CDRa3 and a second polypeptide comprising a variable domain VB comprising CDRb1, CDRb2 and CDRb3. Also provided are nucleic acids encoding the antigen binding proteins, vectors comprising the nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins. The invention further provides the antigen binding proteins for use in medicine and a method of producing the antigen binding protein.



WO 2023/006828 A1